Improving anti-EGFR therapy in HNSCC by targeting the growth factor receptor co-activation network
MetadataShow full item record
Worldwide, head and neck squamous cell carcinoma (HNSCC) is the 6ᵗʰ most common cancer. Because the epidermal growth factor receptor (EGFR) is overexpressed in about 90% of HNSCC tumors, molecularly targeted therapy against EGFR was thought to hold promise for HNSCC treatment. Cetuximab, a monoclonal antibody against EGFR, has been approved to treat HNSCC in the US, yet the 5-year survival rate for HNSCC remains at 40-50%. The modest effect of cetuximab on survival may be limited by intrinsic and acquired resistance or by the activity of alternative growth factor pathways in HNSCC. Herein, I ...